A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice

International Journal of Cancer

Volumn 138, Issue 4, 2016, Pages 1013-1023

  Fang, Jinxu ^a   Xiao, Liang ^a   Joo, Kye Il ^a   Liu, Yarong ^a   Zhang, Chupei ^a   Liu, Shuanglong ^b   Conti, Peter S ^b   Li, Zibo ^b   Wang, Pin ^a,c  

^a University of Southern California   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

breast cancer; fibroblast activation protein; immunotoxin; positron emission tomography; tumor microenvironment; tumor associated fibroblast

Indexed keywords

ALPHA FIBROBLAST ACTIVATION PROTEIN PSEUDOMONAS EXOTOXIN A; FIBROBLAST ACTIVATION PROTEIN; IMMUNOTOXIN; PACLITAXEL; SERINE PROTEINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GELATINASE; MEMBRANE PROTEIN; SEPRASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; FIBROBLAST; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TUMOR ASSOCIATED FIBROBLAST; TUMOR MICROENVIRONMENT; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DISEASE MODEL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BALB 3T3 CELLS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GELATINASES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MEMBRANE PROTEINS; MICE; REAL-TIME POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES;

EID: 84954380288     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29831     Document Type: Article

References (53)

1. Tlsty TD, Coussens LM., Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-50.
2. Bhowmick NA, Neilson EG, Moses HL., Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
3. Kalluri R, Zeisberg M., Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
4. Balkwill F., Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-41.
5. Balkwill F., Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50.
6. Kessenbrock K, Plaks V, Werb Z., Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
7. Singer CF, Kronsteiner N, Marton E, et al., MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002; 72: 69-77.
8. Roomi MW, Monterrey JC, Kalinovsky T, et al., Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 2009; 21: 1323-33.
9. Kojima Y, Acar A, Eaton EN, et al., Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-14.
10. Kraman M, Bambrough PJ, Arnold JN, et al., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330: 827-30.
11. Mishra P, Banerjee D, Ben-Baruch A., Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011; 89: 31-9.
12. Liu R, Li H, Liu L, et al., Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 2012; 13: 123-9.
13. Kakarla S, Chow K, Mata M, et al., Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013; 21: 1611-20.
14. Brennen WN, Rosen DM, Wang H, et al., Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012; 104: 1320-34.
15. Tuxhorn JA, Ayala GE, Smith MJ, et al., Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8: 2912-23.
16. Santos AM, Jung J, Aziz N, et al., Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119: 3613-25.
17. Kelly T, Huang Y, Simms AE, et al., Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol 2012; 297: 83-116.
18. Brennen WN, Isaacs JT, Denmeade SR., Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012; 11: 257-66.
19. Jacob M, Chang L, Pure E., Fibroblast activation protein in remodeling tissues. Curr Mol Med 2012; 12: 1220-43.
20. Huang Y, Simms AE, Mazur A, et al., Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011; 28: 567-79.
21. Lee HO, Mullins SR, Franco-Barraza J, et al., FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011; 11: 245
22. Cheng JD, Valianou M, Canutescu AA, et al., Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005; 4: 351-60.
23. Wolf BB, Quan C, Tran T, et al., On the edge of validation-cancer protease fibroblast activation protein. Mini Rev Med Chem 2008; 8: 719-27.
24. Narra K, Mullins SR, Lee HO, et al., Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007; 6: 1691-9.
25. Tsai TY, Yeh TK, Chen X, et al., Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J Med Chem 2010; 53: 6572-83.
26. Walsh MP, Duncan B, Larabee S, et al., Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors. PLoS One 2013; 8: e58860
27. Pastan I, Hassan R, Fitzgerald DJ, et al., Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6: 559-65.
28. Pastan I, Hassan R, FitzGerald DJ, et al., Immunotoxin treatment of cancer. Annu Rev Med 2007; 58: 221-37.
29. Kioi M, Seetharam S, Puri RK., Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008; 7: 1579-87.
30. Madhumathi J, Verma RS., Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 2012; 15: 300-9.
31. Yang L, Yang H, Rideout K, et al., Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26: 326-34.
32. Brocks B, Garin-Chesa P, Behrle E, et al., Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med 2001; 7: 461-9.
33. Xiao L, Hung KC, Takahashi TT, et al., Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery. ACS Chem Biol 2013; 8: 967-77.
34. Li Z, Jin Q, Huang C, et al., Trackable and targeted phage as positron emission tomography (PET) agent for cancer imaging. Theranostics 2011; 1: 371-80.
35. Benedict CA, MacKrell AJ, Anderson WF., Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997; 201: 223-31.
36. Mocellin S, Marincola FM, Young HA., Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78: 1043-51.
37. Connolly EC, Freimuth J, Akhurst RJ., Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012; 8: 964-78.
38. Ferrara N, Kerbel RS., Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
39. Keophiphath M, Rouault C, Divoux A, et al., CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler Thromb Vasc Biol 2010; 30: 39-45.
40. Holden SA, Lan Y, Pardo AM, et al., Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001; 7: 2862-9.
41. Zhang Y, Xiang L, Hassan R, et al., Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006; 12: 4695-701.
42. Folkman J., Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
43. Hofmeister V, Schrama D, Becker JC., Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008; 57: 1-17.
44. Albini A, Sporn MB., The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7: 139-47.
45. Swartz MA, Iida N, Roberts EW, et al., Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72: 2473-80.
46. Hanahan D, Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
47. Conway EM, Collen D, Carmeliet P., Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-21.
48. Jain RK., Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-93.
49. Loeffler M, Kruger JA, Niethammer AG, et al., Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-62.
50. Liao D, Luo Y, Markowitz D, et al., Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009; 4: e7965
51. Wen Y, Wang CT, Ma TT, et al., Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010; 101: 2325-32.
52. Tran E, Chinnasamy D, Yu Z, et al., Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210: 1125-35.
53. Mazor R, Eberle JA, Hu X, et al., Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci USA 2014; 111: 8571-6.